乳腺癌治疗进展:乳腺癌术前立体定向体部放疗(SBRT)的系统综述
本系统综述检索多个数据库,纳入10项前瞻性临床试验(7项II期、3项I期)共188例患者,评估术前立体定向体部放疗(SBRT)的早期毒性和美容结局,次要分析病理完全缓解率、晚期毒性、患者选择标准和放疗方案。早期结果显示美容效果优良且毒性低。
要点
- 术前SBRT的急性G2毒性发生率为0-17%,晚期G2毒性为0-19%,G3毒性罕见。
- 美容结局优良率为85-100%,一般者为0-10%,仅1例患者美容效果差。
- 病理完全缓解率随SBRT与手术间隔延长及联合新辅助全身治疗而升高(最高达42%和90%)。
核心结论
- 术前SBRT显著缩短总体治疗时间,并能够最小化照射体积。
- 早期结果提示美容效果优良且毒性低。
研究设计与样本
- 系统文献综述,检索PubMed、Scopus、Web of Science、Cochrane、ScienceDirect和ClinicalTrials.gov,遵循PRISMA 2020指南。
- 纳入10项前瞻性临床试验(7项II期、3项I期),共188例患者(年龄18-75岁,cT1-T3 cN0-N3 cM0,主要为ER/PgR阳性、HER2阴性状态)。
- 中位随访15个月(范围3-30个月)。
主要发现
- 五项研究采用单次SBRT(15-21Gy),其余研究采用分次SBRT(19.5-31.5Gy分3次)。
- SBRT至手术的时间间隔为9.5周(范围1-28周)。
- 急性和晚期G2毒性发生率分别为0-17%和0-19%,G3毒性罕见。
- 美容结局优良率为85-100%,一般者为0-10%,仅1例患者美容效果差。
- 病理完全缓解率存在差异,SBRT与手术间隔较长及联合新辅助全身治疗时较高(分别最高达42%和90%)。
关键数值与推荐
- 患者选择标准:年龄18-75岁,cT1-T3 cN0-N3 cM0,主要为ER/PgR阳性、HER2阴性状态。
- 放疗方案:单次SBRT 15-21Gy(五项研究)或分次SBRT 19.5-31.5Gy分3次(其余研究)。
- SBRT至手术的时间间隔为9.5周(范围1-28周)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast conserving treatment typically involves surgical excision of tumor and adjuvant radiotherapy targeting the breast area or tumor bed. Accurately defining the tumor bed is challenging and lead to irradiation of greater volume of healthy tissues. Preoperative stereotactic body radiotherapy (SBRT) which target tumor may solves that issues. We conducted a systematic literature review to evaluates the early toxicity and cosmetic outcomes of this promising treatment approach. Secondary we reviewed pathological complete response (pCR) rates, late toxicity, patient selection criteria and radiotherapy protocols. We retrieved literature from PubMed, Scopus, Web of Science, Cochrane, ScienceDirect, and ClinicalTrials.gov. The study adhered to the PRISMA 2020 guidelines. Ten prospective clinical trials (7 phase II, 3 phase I), encompassing 188 patients (aged 18-75 years, cT1-T3 cN0-N3 cM0, primarily with ER/PgR-positive, HER2-negative status,), were analyzed. Median follow-up was 15 months (range 3-30). Treatment involved single-fraction SBRT (15-21Gy) in five studies and fractionated (19.5-31.5Gy in 3 fractions) in the rest. Time interval from SBRT to surgery was 9.5 weeks (range 1-28). Acute and late G2 toxicity occurred in 0-17% and 0-19% of patients, respectively, G3 toxicity was rarely observed. The cosmetic outcome was excellent in 85-100%, fair in 0-10% and poor in only 1 patient. pCR varied, showing higher rates (up to 42%) with longer intervals between SBRT and surgery and when combined with neoadjuvant systemic therapy (up to 90%). Preoperative SBRT significantly reduce overall treatment time, enabling to minimalize volumes. Early results indicate excellent cosmetic effects and low toxicity.
引用
- Bilski M, Konat-Bąska K, Zerella MA, et al. Advances in breast cancer treatment: a systematic review of preoperative stereotactic body radiotherapy (SBRT) for breast cancer. Radiat Oncol. 2024. PMID: 39095859. doi:10.1186/s13014-024-02497-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。